Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies specific for varicella zoster virus

An antibody and antibody fragment technology, applied in the direction of antibodies, viral peptides, antiviral agents, etc., can solve the problems of non-elimination, reduced treatment, and persistent disease

Inactive Publication Date: 2010-03-03
RIBOVAX BIOTECHNOLOGIES SA
View PDF14 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] Despite major improvements brought about by vaccines and systemic antivirals, the disease persists
Treatment reduces but does not eliminate many VZV complications that may manifest in unpredictable patterns

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies specific for varicella zoster virus
  • Antibodies specific for varicella zoster virus
  • Antibodies specific for varicella zoster virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Example 1: Expression and Selection of Human Fabs Binding VZV Protein Extracts in ELISA

[0092] Materials and methods

[0093] library construction

[0094] According to the literature (Burioni et al., 1998; "Phage Display: A laboratory Manual", Burton DR et al., CSHL Press, 2001), cDNAs encoding the heavy and light chains of human IgG1 were obtained from lymphocytes obtained from From a VZV-seropositive individual. According to the technique described in PCT patent application WO07 / 007154, phage libraries are constructed using cloning cassettes (or cassettes) compatible with pDD vectors, and Fabs are expressed on the surface of recombinant phage in the library.

[0095] Human Fab selection was performed by pDD-based panning (or panning) of the Fab library and sequencing of positive clones as described in the literature (Burioni R et al. 1998).

[0096] The CDRs of specific Fabs were predicted by comparison and sequence alignment provided by IMGT / V-QUEST (Giudicel...

Embodiment 2

[0112] Example 2: Performance of DDF-VZV1 and DDF-VZV2 tested on VZV-infected cell cultures

[0113] Materials and methods

[0114] Neutralization assay of VZV-specific human Fab

[0115] Use 10 4 -10 5 MRC-5 cells were subjected to plaque reduction assays in Costar 24-well plates into which they were plated under conditions in which they generally formed confluent monolayers after 72 hours of incubation at 37°C. The VZV strains used were clinical isolates.

[0116] The Fab was partially purified as indicated in Example 1 and was prepared at various concentrations with the same volume of stock solution of VZV-free cells (ELLEN strain; infection 0.01 multiplicity (or multiplicity)) suspended in maintenance medium (maintenance medium) (0.01, 0.1, 1, 10 and 50 μg / ml) were mixed. Controls consisted of the same volume of maintenance medium and virus in the absence of Fab (blank) or in the presence of an irrelevant Fab specific for human hepatitis C virus (e137; Bugli F et al...

Embodiment 3

[0126] Example 3: Production and confirmation of DDF-VZV1 and DDF-VZV2 using pDD-compatible expression vectors

[0127] Materials and methods

[0128] Design and construction of pDLac-FLAGhis vector

[0129] The pDD vector containing the DDb cassette in which the Zeocine gene is used as a marker gene (WO 07 / 007154) has been modified by replacing the SpeI-NheI fragment including the cp3* sequence with a NheI-SpeI synthetic linker containing two tags and a stop codon. grooming. Such a linker was created by annealing two oligonucleotides (SEQ ID NO: 15 and 16). The resulting double-stranded DNA molecules were digested with SpeI and NheI and prepared for the step of cloning into the corresponding linearized pDD vectors. The final vector was characterized by restriction and sequence analysis to confirm the in-frame insertion of the two tag sequences. The LacI gene was PCT amplified from a commercially available plasmid called pET28 (Invitrogen) and then inserted into the StuI...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection.

Description

technical field [0001] The present invention relates to novel antibody sequences isolated from phage display libraries having biological activity specific to viruses. Background technique [0002] Phage display technology exploits the small size and adaptability of the genome of filamentous phages (such as M13) that infect bacterial cells (such as Escherichia coli cells) to clone, select and genetically engineer polypeptides expressed on their surface (antibody fragments, bioactive peptides, enzymes, etc.) and can exert biological functions after they interact with the target (target). [0003] Various cloning and expression strategies, vectors, libraries, methods for propagating phage as well as screening assays have been developed for different applications, as described in papers (Bradbury A and Marks J, 2004; Mancini et al., 2004; Conrad U and Scheller J, 2005; Hust M and Dubel S, 2005), and books ("Phage Display: A Practical Approach", vol.266, ed. Clackson and Lowman ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/08A61P31/22A61K39/395C07K14/04
CPCC07K2317/21A61K2039/507C07K16/088C07K2317/55A61P31/12A61P31/22C07K16/08C07K14/04A61K39/395
Inventor 罗伯托·布廖尼马西莫·克莱门蒂
Owner RIBOVAX BIOTECHNOLOGIES SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com